References
- Basarab GS, Kern G, McNulty J, et al. (2015a). Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep 5:11827
- Basarab GS, Doig P, Galullo V, et al. (2015b). Discovery of novel DNA gyrase inhibiting spiropyrimidinetriones: benzisoxazole with N-linked oxazolidinone substituents leading to a clinical candidate (ETX0914). J Med Chem 58:6264–82
- Basarab GS, Galullo V, DeGrace N, et al. (2014). Synthesis of a tetrahydronaphthyridine spiropyrimidinetrione DNA gyrase inhibiting antibacterial agent differential substitution at all five carbon atoms of pyridine. Org Lett 16:6456–9
- Berger JM, Gamblin SJ, Harrison SC, Wang JC. (1996). Structure and mechanism of DNA topoisomerase II. Nature 379:225–32
- Bryskier A. (1993). Fluoroquinolones: mechanisms of action and resistance. Int J Antimicrob Agents 2:151–83
- Collin F, Karkare S, Maxwell A. (2011). Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 92:479–97
- Dalhoff A. (2012). Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis 2012:976273
- Guo J, Joubran C, Luzietti RA, et al. (2015). In vitro and in vivo metabolism of 14C-AZ11, a novel inhibitor of bacterial DNA gyrase/type II topoisomerase. Xenobiotica 45:158–70
- Hooper DC. (2001). Emerging mechanisms of fluoroquinolone resistance. Emerging Infect Dis 7:337–41
- Huband MD, Cohen MA, Zurack M, et al. (2007). In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob Agents Chemother 51:1191–201
- Kitamura S, Sugihara K, Kuwasako M, Tatsumi K. (1997). The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol 49:253–6
- Mannens G, Huang ML, Meuldermans W, et al. (1993). Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 21:1134–41
- Maruri F, Sterling TR, Kaiga AW, et al. (2012). A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67:819–31
- Ruble CJ, Hurd AR, Johnson TA, et al. (2009). Synthesis of (-)-PNU-286607 by asymmetric cyclization of alkylidene barbiturates. J Am Chem Soc 131:3991–7
- Gonzalez FJ, Nebert DW, Hardwick JP, Kasper CB. (1985). Complete cDNA and protein sequence of a pregnenolone 16 _-carbonitrile-induced cytochrome P-450. A representative of a new gene family. J Biol Chem 260:7435–41
- Gonzalez FJ, Song BJ, Hardwick JP. (1986). Pregnenolone 16 alpha-carbonitrile-inducible P-450 gene family: gene conversion and differential regulation. Mol Cell Biol 6:2969–76
- Sanyal G, Doig P. (2012). Bacterial DNA replication enzymes as targets for antibacterial drug discovery. Expert Opin Drug Discov 7:327–39
- Shigemura K, Tanaka K, Yamamichi F, et al. (2012). Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: a statistical analysis study. Int J Antimicrob Agents 40:516–20